The successful development of efficient and safe gene delivery vectors continues to be a major obstacle to gene delivery in stem cells. In this study, we have developed an elastin-like polypeptide (ELP)-mediated adeno-associated virus (AAV) delivery system for transducing fibroblasts and human neural stem cells (hNSCs). AAVs have significant promise as therapeutic vectors because of their safety and potential for use in gene targeting in stem cell research. ELP has been recently employed as a biologically inspired 'smart' biomaterial that exhibits an inverse temperature phase transition, thereby demonstrating promise as a novel drug carrier. The ELP that was investigated in this study was composed of a repetitive penta-peptide with [Val-Pro-Gly-Val-Gly]. A novel AAV variant, AAV r3.45, which was previously engineered by directed evolution to enhance transduction in rat NSCs, was nonspecifically immobilized onto ELPs that were adsorbed beforehand on a tissue culture polystyrene surface (TCPS). The presence of different ELP quantities on the TCPS led to variations in surface morphology, roughness and wettability, which were ultimately key factors in the modulation of cellular transduction. Importantly, with substantially reduced viral quantities compared with bolus delivery, ELP-mediated AAV delivery significantly enhanced delivery efficiency in fibroblasts and hNSCs, which have great potential for use in tissue engineering applications and neurodegenerative disorder treatments, respectively. The enhancement of cellular transduction in stem cells, as well as the feasibility of ELPs for utilization in three-dimensional scaffolds, will contribute to the advancement of gene therapy for stem cell research and tissue regenerative medicine.
INTRODUCTION
The elucidation of molecular or environmental cues that can regulate stem cell proliferation and differentiation is a prerequisite for developing stem cell technologies. However, precise control over stem cell fates is still a challenge, and improper differentiation or extensive proliferation of stem cells can elicit deleterious consequences, such as tumorigenesis. To circumvent the challenges associated with current stem cell technologies, gene delivery of transcription factors or regulatory molecules, which can accelerate cell fate decisions, can serve as a powerful means to regulate stem cell functions. [1] [2] [3] Critical issues, however, still remain in developing efficient gene delivery systems.
Adeno-associated virus (AAV) is a 4.7 kb single-stranded DNA virus that is a highly safe and efficient vehicle for the delivery and sustained expression of therapeutic genes in a variety of human gene therapy applications, such as treatment for Parkinson's disease, 4 hemophilia B (by delivering the Factor IX gene) 5 and Leber's congenital amaurosis. 6, 7 AAV has the capability to deliver genes to both dividing and non-dividing cells, such as muscle, 8 brain 9 and retina cells. 10 Furthermore, its single-stranded nature allows for homologous recombination at a significant frequency relative to other gene carriers, 11 which increases its potential for use in numerous stem cell applications including gene correction, precise stem cell regulation and creation of disease models. Despite this promise, however, no AAV serotypes have been found with effective properties for infecting the majority of stem cells. [12] [13] [14] In a previous study utilizing directed evolution, a novel AAV vector (AAV r3.45) was created with enhanced transduction efficiency for rat adult neural stem cells (NSCs), thus enhancing its potential for use in applications ranging from basic stem cell biology to clinical translation. 12 Interfacing AAV vectors with biomaterials has great potential to further enhance gene delivery to stem cells. Immobilization of viral vectors within or onto a biomaterial, which can serve as a substrate for cell adhesion, can place viral vectors directly inside the cell microenvironment for subsequent cellular internalization and may thereby function to overcome barriers to gene transfer such as mass transfer limitations. 15 Additionally, biomaterial-based gene delivery can provide localized gene expression adjacent to the substrate and prevent systemic spread of AAV upon injection. 16 Furthermore, biomaterials can be harnessed to protect vectors from pre-existing neutralizing antibodies and may potentially mitigate cellular immune responses against the vector that can preclude the potential for repeat administration. 17, 18 Taken together, it is assumed that maintaining a high local concentration of AAV vectors within the stem cell microenvironment and increasing the extent of physical contact with stem cells may further enhance the delivery efficiency of the AAV (that is, AAV r3.45) to stem cells. Both an understanding of biomaterial design parameters and the selection of proper biomaterials are highly critical to fully maximize the advantages of biomaterials in AAV gene delivery.
Elastin-like polypeptide (ELP), which is a thermally responsive protein-based polymer, has been recently proposed as a novel drug carrier. [19] [20] [21] ELPs are composed of the repetitive penta-peptide (ValPro-Gly-X-Gly) n where X is any amino acid except for proline. ELPs are biologically inspired 'smart' biomaterials that exhibit an inverse temperature phase transition, demonstrating an aqueous phase below transition temperature (T t ) and an insoluble gel phase above the temperature. 22 Coacervation of ELPs above the transition temperature enabled them to be utilized as tumor-targeting agents; ELPs accumulate around tumor sites upon systemic administration because of the hyperthermia of the tumor. 23, 24 Additionally, ELPs (for example, T t ) can be modulated by the choice of the X amino acid, the number of the repeat units (n) in the ELP chain, the pH and the salt concentration. Thus, ELPs can be versatile candidates for the development of novel controlled drug delivery systems 21, 25 and tissue engineering scaffolds. 26, 27 In this report, we investigated the efficacy of ELPs for promoting AAV-mediated gene delivery to human neural stem cells (hNSCs), which are centrally involved in the development of the nervous system. 28 A novel AAV vector (that is, AAV r3.45), which was engineered by directed evolution to enhance gene transfer to rat NSCs in a previous study, 12 has been employed to interact with ELPs and subsequently infect hNSCs. The physical properties of the ELP-mediated AAV delivery system were initially optimized using fibroblasts, which are known to be nonpermissive to wild-type AAV serotype 2, and several systems were chosen to infect hNSCs. The successful development of an efficient AAV delivery system to hNSCs would aid in the treatment of numerous neurodegenerative disorders, such as Parkinson's disease and stroke.
RESULTS AND DISCUSSION

Production of ELPs
ELPs composed of a repeating penta-peptide (that is, [VPGVG] 128 ) were successfully generated. They possessed thermally responsive properties and were capable of undergoing a reversible phase transition. At a temperature below the transition temperature (T t ), ELP molecules assume an extended conformation and thus are soluble in aqueous solution; however, they become insoluble and aggregate rapidly at a temperature above the T t . The phase transition of ELP multimers encoding [VPGVG] 128 was demonstrated using a spectrophotometer at 350 nm (data not shown). The resulting phase transition temperature (T t ) was B22 1C; thus, the multimers underwent gelation under cell culture conditions (that is, 37 1C).
Characterization of ELP adsorptions onto tissue culture polystyrene surface (TCPS)
The surface -association of ELPs was related to the initial concentration of ELPs before adsorption and the incubation times on the TCPS. ELPs were initially suspended in 200 ml of phosphate-buffered saline (PBS) at different concentrations (2.5, 5, 10 and 12.5 mg ml -1 ) and incubated onto TCPS for various incubation times (2, 4 and 6 h) at 37 1C. Thus, the total quantities of ELPs initially employed for surface adsorption were 0.5, 1.0, 2.0 and 2.5 mg. Adsorbed quantities were increased as incubation times increased (Figure 1a) , and approximately 0.5, 1.0, 1.7 and 2.0 mg of ELPs were adsorbed on the TCPS at 4 h post adsorption. After the 4-h incubation, no additional ELP adsorptions were observed on each surface, and thus the incubation time for ELP adsorption was fixed at 4 h for further analysis. The quantity in the legend refers to the actual ELP amount remaining on the TCPS. Protein adsorption onto solid surfaces typically varies with changes in surface charge, polarity and wettability (that is, hydrophobicity), and it is well known that proteins adhere more tightly to non-polar, charged and hydrophobic surfaces. 29 Because the ELP utilized in this study (that is, [VPGVG] 128 ) is nonpolar and has an almost neutral charge, hydrophobic interactions may play a crucial role in the primary driving forces for physical adsorption of ELPs onto the TCPS.
The altered surface chemistry induced by ELP adsorption was confirmed with infrared spectroscopy and contact angle measurements (Figures 1b and c) . The stretching vibration of the C¼O within the peptide group, which is weakly coupled with the in-plane N-H bending and the C-N stretching vibration, can be identified as amide I bands in the region between B1700 and 1500 cm À1 . 30 These characteristic peaks within the designated infrared spectrum were observed for the ELP-treated surfaces as opposed to the TCPS, which was set as the background (Figure 1b) . Additionally, ELP adsorption increased the wettability of the surfaces as determined by contact angle measurements ( Figure 1c ). The ELP-treated surfaces had a low contact angle (o501) when compared with the TCPS (B701). The increased presence of ELPs, which consequently increase the quantity of functional groups carrying oxygen (such as carboxylic acids or esters), may result in an increased wettability of the surface, thus causing changes in affinity for the subsequent protein adsorption (that is, AAV r3.45) and cell attachment. 31 Immobilization of AAV vectors onto ELP surfaces AAV r3.45 vectors, which demonstrated enhanced transduction efficiency in rat NSCs when compared with wild-type AAV serotype 2 in a previous study, 12 were nonspecifically immobilized by incubating the vectors on the surface presenting ELPs. The amount of AAV vectors adsorbed onto the surfaces varied with the surface quantities of ELPs ( Figure 2a ). Interestingly, surface adsorption of AAV vectors was not proportional to the quantities of ELPs. The surface presenting 1.0 mg of [VPGVG] 128 demonstrated the highest capacity to mediate AAV adsorption (B65%) relative to the surfaces containing the lower (0.5 mg) or higher (1.7 and 2.0 mg) quantity of ELPs, implying that interactions between AAV and ELPs are dependent upon the comprehensive properties of ELP surfaces, such as total ELP quantities, wettability and surface roughness. Incubation of AAV vectors on the ELP substrate for 24 h resulted in surface quantities of at least 1.0Â10 9 (for NIH3T3) or 5.0Â10 9 (for hNSCs) viral genomic particles, which corresponds to immobilization of more than 55% of the AAV vectors initially employed for surface adsorption. All ELP surfaces exhibited significantly higher affinities (450%) to AAV vectors when compared with TCPS (B10%).
Dissociation of AAV vectors from ELP-treated surfaces
The release kinetics of AAV vectors from ELP-treated surfaces were dependent upon the quantity of ELPs adsorbed onto the TCPS (Figure 2b ). However, o14% of the immobilized AAV vectors were released after 4 days of incubation, indicating that the majority of the surface-bound AAV vectors were retained. A surface that does not prematurely release vectors may be a prerequisite for localized gene delivery to cells that come into contact with a vector-loaded substrate. 16 The release during the first day ranged from 2.65 ± 1.30% to 9.68 ± 4.27% for the different quantities of ELPs, with the lowest quantity of ELPs (0.5 mg) providing the smallest initial burst. Treatments with the smallest quantity of ELPs (that is, 0.5 mg) led to extremely slow release rates, with B4% cumulative release at 4 days. Enhanced hydrophobicity of the surfaces treated with the smallest quantity of ELPs, as shown in Figure 1c , may have caused tighter interactions with AAV vectors than the other surfaces treated with higher ELP quantities (that is, 1.0, 1.7 and 2.0 mg), ultimately delaying AAV dissociation from the surface. Cellular transduction typically involves cell culture for 48 h, which corresponds to a dissociation of 3 to 12% of immobilized AAV vectors.
Characterization of surfaces treated with ELPs and AAV Before investigating cellular transduction, topographical changes of AAV/ELP surfaces were examined using atomic force microscopy and field-emission scanning electron microscopy ( Figure 3) . Each ELPtreated surface with or without AAV adsorption was imaged using atomic force microscopy and field-emission scanning electron microscopy, revealing that the surface roughness was enhanced as a function of imaging scale and ELP quantities (Figures 3a and d) . The root mean squared (rms) roughness values gradually increased with the imaging scale and the ELP quantity (Figures 3b and c) . Additionally, ELP-treated surfaces carrying AAV vectors had higher magnitudes of roughness than those without AAV vectors, whereas AAV adsorption onto the TCPS did not contribute substantially to differences in surface roughness. This observation demonstrates that additional topographical alterations of ELP-treated surfaces upon AAV adsorption result from a specific interaction, such as a steric hindrance, between two proteins (that is, components of AAV vectors and ELPs). 32 These altered structural features can potentially lead to variations in cellular attachment, 33 ultimately influencing cellular transduction.
Nonspecific adsorption or dissociation of AAV vectors can occur through molecular interactions between AAV vectors and the ELP substrate; these interactions include electrostatic interactions, van der Waals forces, hydrophobic interactions and structural rearrangement of the adsorbing molecules. 34, 35 The icosahedral shapes of macromolecules (that is, AAV), which comprise an assembly of three capsid proteins (that is, VP1, VP2 and VP3 with molecular weight of 90, 72 and 60 kDa, respectively), 36 may be preferentially adsorbed onto rough ELP surfaces rather than immobilized onto relatively flat TCPS surfaces. Additionally, because the electrostatic charges of AAV r3. 45 and ELP [VPGVG] 128 have been identified as almost neutral (data not shown), interactions between AAV vectors and ELP surfaces may be primarily generated by van der Waals forces, structural rearrangement or hydrophobic interactions. The combinatorial effect of these interactions may cause considerably different profiles of both adsorption and dissociation of AAV vectors, further influencing cellular transduction and viability.
Enhanced infectivity with AAV/ELP surfaces ELP-mediated AAV r3.45 delivery significantly enhanced cellular transduction of NIH3T3 and hNSCs when compared with the bolus delivery of AAV r3.45 ( Figure 4) . To test the enhancement of ELPmediated AAV r3.45 delivery, NIH3T3 cells or hNSCs were incubated on ELP-treated surfaces presenting surface-bound AAV r3.45 vectors. After 1, 2 and 4 days, green fluorescence protein (GFP)-expressing cells were quantified using flow cytometry (Figures 4a and c) . Bolus deliveries of two different quantities of AAV vectors, corresponding to 100 and 60% of the initial vector available for surface adsorption, were delivered to investigate the performance of the substrate-mediated system. Bolus delivery of 100% AAV r3.45 involved the direct addition of the same vector quantity utilized for initial surface adsorption (that is, 2Â10 9 viral genomic particles for NIH3T3 and 1.0Â10 10 viral genomic particles for hNSCs). Viral quantities for 60% AAV r3.45 bolus delivery were approximately equal to the amount of vectors immobilized on the ELP substrate before cell seeding (that is, 1.2Â10 8 viral genomic particles for NIH3T3 and 6.0Â10 9 viral genomic particles for hNSCs). The initial viral quantity corresponded to the multiplicity of infection (MOI) 10 5 , which is defined as the ratio of viral particles to cells. As a consequence, for NIH3T3 infection, AAV vectors adsorbed onto the surfaces containing 0.5, 1.0 and 1.7 mg of ELPs demonstrated similar or slightly improved cellular transduction when compared with 100% bolus delivery. However, substratemediated delivery resulted in significantly enhanced transduction relative to 60% bolus delivery (Po0.05). Similarly, for hNSC infection, ELP-mediated AAV delivery (that is, 1.0 and 1.7 mg quantities of ELPs) significantly increased transduction efficiencies when compared with both 100 and 60% bolus delivery. However, for both NIH3T3 and hNSC infection, the substrate-mediated system possessing the highest ELP quantity (that is, 2.0 mg) exhibited similar or significantly reduced cellular transduction relative to bolus delivery.
The ELP-mediated AAV delivery system significantly reduced the viral quantities required for inducing cellular transduction when compared with bolus delivery. Based on analysis of the dissociation of AAV vectors from ELP-treated surfaces (that is, Figure 2b) , actual viral quantities delivered to cells adhered to ELP-treated surfaces may be o14% of the adsorbed quantity at a specified time point. For example, the quantities of viral vectors, which are released over a 2-day period and subsequently become available for cellular transduction, ranged from 3.0Â10 7 to 1.2Â10 8 viral particles for NIH3T3 (2Â10 4 cells per well) and from 1.5Â10 8 to 6.0Â10 8 viral particles for hNSCs (1Â10 5 cells per well), corresponding to MOIs of 1.5Â10 2 to 6.0Â10 3 for both cell types. These quantities are one order of magnitude lower than that of the 60% bolus delivery. Even with one order of magnitude lower MOI (that is, 6Â10 3 ), the ELP-mediated AAV delivery system exhibited significantly increased delivery efficiencies in NIH3T3 and hNSC infections (Figures 4a-d) . This outcome confirms the efficacy of the substrate-mediated delivery system in terms of gene delivery efficiency, which is consistent with previous studies. 16, 37, 38 The substrate-mediated delivery system, which has been termed reverse or solid-phase delivery, involves reversible interactions between the vector and the material that delays release yet allows for cell internalization. This strategy allows for the biomaterial to be manipulated before vector adsorption, thereby avoiding exposure of the vector to any harsh biomaterial processing steps and may function to more effectively maintain the activity of the vector. 15 Immobilization of viral vectors onto biomaterial surfaces followed by implantation into target regions can potentially lead to efficient gene delivery. 39, 40 Immobilization of the vectors to material surfaces that also support adhesion may colocalize the cells and the vector, and may function to overcome mass transfer limitations. 15 Maintaining a high local concentration of viral vectors within the cellular microenvironment and placing the vectors into sustained contact with the target cells can be highly effective to enhance the delivery efficiency of viral vectors with significantly reduced viral quantities.
The delayed or sustained release of viral vectors from a substrate can increase the delivery efficiency and prohibit the extensive proliferation of stem cells, which potentially elicits deleterious consequences. As seen in Figure 4d , the abrupt exposure of high quantities of AAV r3.45 to hNSCs during bolus delivery caused hNSCs to form neurospheres earlier (at 2 days), whereas hNSCs that were infected via the ELP-mediated delivery mechanism formed neurospheres at 4 days post infection, similar to the negative control (that is, cell culture without infection). Additionally, because cells residing within the spheres may be limited to contact with AAV vectors, maintaining the adherence of hNSCs on the surface for an extended time period may trigger the chances of cellular transduction via the maximization of physical contact.
Cell viability on AAV/ELP surfaces Cells adhered to each surface maintained metabolic activity for 4 days without demonstrating a significant reduction in metabolic function, as evaluated using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays at 1, 2 and 4 days post infection ( Figure 5 ). Substrate-mediated systems yielded comparable or slightly reduced cellular metabolic activities until 2 days when compared with controls (that is, cells growing on TCPS without AAV infection), presumably because of overgrowth on limited surface areas. However, the majority of the systems (including bolus delivery) resulted in the recovery of viabilities at day 4 to levels similar to the control. These results imply that ELP-mediated AAV delivery systems do not have deleterious effects on cell proliferation or viability, with the exception of the ELP-treated surface possessing the highest quantity of ELPs (that is, 2.0 mg, but only in NIH3T3 infection; Figures 5b and c) . This surface also demonstrated the highest hydrophilicity.
Altered surface chemistry, such as surface wettability or topographical changes, can vary cellular attachment or behavior at the surface and ultimately influence cell viability as well as cellular transduction. Although the suitable wettability of artificial surfaces depends upon cell type, the most preferable level of wettability (that is, water contact angle) for effective cell attachment on artificial materials has been reported to range from 40 to 701. 31 Consistently, the surface with 2.0 mg ELPs, which exhibited a contact angle o401, induced low cell viability during the entire range of culture time points (up to 4 days, although only in NIH3T3 cells; Figure 5b) . Consequently, the transduction of NIH3T3s using the highest ELP quantities was even less efficient than that obtained by bolus delivery, implying that the enhancement of cellular attachment and cell viability is related to an increase in cellular transduction. Additionally, as shown in Figure 5a , the edge of the NIH3T3 cells adhered to the ELP-treated surface (that is, 2.0 mg of ELPs) was partially lifted up. This alteration may be an indicator that the cells were initiating cellular detachment, possibly causing the low viability and low transduction observed in comparison with bolus delivery.
In conclusion, viral gene delivery is a powerful means for the regulation of stem cell function. Therefore, the development of gene delivery vectors and systems with enhanced abilities to infect stem cells efficiently is critical to upgrade the level of gene delivery technology for stem cell therapy. In this report, we demonstrated a novel substrate-mediated AAV delivery system using ELPs, which demonstrated significantly enhanced cellular transduction efficiency in hNSC infections with significantly reduced viral quantities. The development of gene delivery systems with enhanced abilities to infect stem cells efficiently has numerous applications, ranging from basic stem cell biology to stem cell therapy or disease models. Additionally, we anticipate that the level of gene expression can be easily regulated by controlling variables affecting the binding capacity (for example, bound quantity, wettability and surface roughness), implying that 'smart' gene delivery devices are a possibility. Finally, because the ELP substrate can be easily extended to three-dimensional tissue engineering scaffolds, the system proposed in this report is likely to be easily applicable to tissue regenerative medicine.
MATERIALS AND METHODS
Cell culture
For viral packaging, AAV 293 cells (Stratagene, La Jolla, CA, USA) were cultured in Dulbecco's modified Eagle medium (Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (Invitrogen) and 1% penicillin and streptomycin (Invitrogen) at 37 1C and 5% CO 2 . Fibroblasts (NIH3T3) and fetal hNSCs (13 weeks of gestational age) were cultured for the measurement of cellular transduction. NIH3T3 cells were cultured in Dulbecco's modified Eagle medium with 10% fetal bovine serum and 1% penicillin/streptomycin at 37 1C and 5% CO 2 . Human NSCs were derived from the telencephalon (HFT13) as previously described 41 and cultured in Dulbecco's modified Eagle medium/F12 (Invitrogen) containing N-2 supplement, 20 ng ml -1 of fibroblast growth factor 2, 8 mg ml -1 of heparin (Sigma-Aldrich, St Louis, MO, USA) and 10 ng ml -1 of leukemia inhibitory factor (Chemicon, Temecula, CA, USA).
Production and purification of AAV vectors
The AAV r3.45 vector was newly generated through directed evolution specifically for infecting rat NSCs in a previous study. 12 AAV r3.45 carried an insertion of LATQVGQKTA (wt AAV2: 583 LQRGNRQA-), where LA and A are linker residues, at amino acid 587 with an additional V719M mutation. 12 Recombinant AAV r3.45 vectors carrying complementary DNA encoding GFP driven by a cytomegalovirus (CMV) promoter were packaged using the transient transfection method. Briefly, an equal mass (17 mg) of three plasmids, including an AAV helper plasmid (carrying a cap3.45), a CMV GFP vector plasmid containing inverted terminal repeat (pAAV CMV GFP SN) and an adenoviral helper plasmid (Stratagene), were transfected via calcium phosphate into AAV 293 cells. 42 The resulting viral vectors were harvested as previously described 43 and purified using heparin column chromatography. 44 Briefly, AAV r3.45 crude lysates were loaded onto 1 ml of HiTrap heparin column (GE Healthcare, Pittsburgh, PA, USA), which was previously equilibrated with Tris buffer (50 mM, pH 7.5) containing 150 mM NaCl. The column was washed with 3 ml of 150 mM NaCl, and elutions were performed with 3 ml of 1 M NaCl. The viral fractions were desalted and buffer exchanged into PBS using Amicon Ultra-15 Centrifugal Filter Units (Millipore, Billerica, MA, USA) according to the manufacturer's instructions (final volume: 200 ml). DNase-resistant genomic titers were determined by quantitative PCR (Mini Opticon, Bio-Rad, Hercules, CA, USA).
Production and purification of ELP
The ELP monomer gene (104 bp) was designed to encode four tandem repeats of Val-Pro-Gly-Val-Gly and was then cloned to the pUC18 (Novagen, Madison, WI, USA) cloning vector at the EcoRI and BamHI restriction sites. To obtain ELP multimers, the ELP monomer gene was multimerized by the 'recursive directional ligation' method. 45 Consequently, ELP multimers encoding [VPGVG] 128 were synthesized and identified by DNA sequencing. The subscript (that is, 128) indicates the number of the repeating unit. These two genes were transferred from the pUC18 cloning vector into the pET32a (Novagen) expression vector, which encodes a hexa-histidine-tag. To confirm that the ELP multimer genes were successfully cloned into the pET32a vector, recombinant plasmids isolated from the resulting transformants were analyzed via 1% agarose gel electrophoresis and sequencing. Positive transformants were inoculated in Luria Bertani medium supplemented with 100 mg ml -1 ampicillin and induced with 1 mM isopropyl-b-D-thiogalactoside. The expressed ELPs were purified by nickel-nitrilotriacetic acid metal-affinity chromatography, characterized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and mass spectrometry, and finally lyophilized until usage. The transition temperature of expressed ELP was determined by a Cary Bio 300 UV visible spectrophotometer (Varian Instruments, Walnut Creek, CA, USA) with the temperature scanning function.
Adsorption of AAV vectors on ELP surfaces
Before immobilizing AAV vectors, ELP (that is, [VPGVG] 128 ) was adsorbed onto polystyrene tissue culture plates (TCPS; 24-well) by varying the concentration of ELP (2.5, 5, 10 and 12.5 mg ml -1 ). Lyophilized ELPs were suspended in PBS (200 ml) and incubated on the TCPS at 37 1C for 4 h for surface adsorption. To remove unbound ELPs, solution of ELPs in PBS utilized for surface adsorption was removed, and the surface was rinsed twice with PBS, which was collected for quantification. Subsequently, ELPs in the collected buffer were quantified using the Bradford protein assay kit (Thermo Scientific, Fremont, CA, USA) according to the manufacturer's instructions. The adsorbed quantity of ELPs was determined by subtracting the amount of ELPs in the collected buffer from the initial quantity of ELPs before adsorption. Purified viral vectors (2Â10 9 or 1Â10 10 genomic particles for NIH3T3 and hNSCs, respectively) were then immobilized onto the ELP surface by incubating the viral stocks at 37 1C overnight. The surface was rinsed two times with PBS to remove unbound AAV, and each cell type (2Â10 4 cells per well; NIH3T3, 1Â10 5 cell per well; hNSC) was seeded onto the surface to test the infectivity. To determine the quantities of the surface-bound AAV vectors, proteinase K solution (Fermentas, Glen Burnie, MD, USA), which consists of Tris-HCl (10 mM), ethylenediaminetetraacetic acid (20 mM) and NaCl (20mM), was directly added to the surface containing the adsorbed vectors, and the quantities of viral genomic particles exposed by proteinazing (that is, surface-bound AAV) were determined by quantitative PCR.
Release kinetics of AAV vectors
An in vitro release assay was conducted to determine the release kinetics of AAV vectors dissociated from ELP surfaces. Cumulative viral release was defined as the ratio of dissociated viral vector quantities to the initial amount of the surface-bound viral vectors. For quantification of the surface-dissociated AAV r3.45 vectors, immobilized AAV r3.45 vectors were incubated with cell-culture media without cell seeding for specified time points (1, 2 and 4 days). At each time point, both cell-culture medium and rinse buffers were collected, and genomic viral particles were quantified using quantitative PCR.
Characterization of AAV/ELP surfaces
The presence of ELPs on the TCPS after adsorption was confirmed by FourierTransform Infrared spectroscopic measurements (Spectrum 100, Perkin Elmer, Waltham, MA, USA). The surfaces of AAV/ELP systems were characterized using field-emission scanning electron microscopy (Hitachi S-800, Tokyo, Japan), atomic force microscopy (Nanoscope 3D SPM NS3D-02, Veeco Instruments Inc., Tokyo, Japan) and a contact angle meter (CAM 101 model, KSV Instruments Ltd, Espoo, Finland). The root mean squared roughness, which was measured by atomic force microscopy and the instrument software, was averaged for each AAV/ELP surface and imaging scale.
Transduction assay
To test the infectivity of the surface-bound AAV vectors, NIH3T3 cells or hNSCs were seeded onto ELP surfaces containing recombinant AAV r3.45 carrying complementary DNA coding GFP driven by the CMV promoter, and the number of GFP-expressing cells was determined by flow cytometry. The percentage of GFP-expressing cells out of the total number of cells on the surface was subsequently calculated and compared with bolus delivery (that is, direct addition method). At 1 day before infection, ELPs and AAV vectors were plated onto 24-well TCPS. At day 1, cells were seeded onto each well at the 
Cell viability
To analyze the viability of cells adhered onto AAV/ELP surfaces, metabolically active cells were stained with MTT (Sigma-Aldrich). Colorimetric changes were detected and compared with changes measured for positive (that is, bolus delivery of 10 5 genomic MOI) and negative controls (that is, no infection). Briefly, each cell (that is, NIH3T3, hNSC) was plated onto AAV/ELP surfaces on 96-well plates (5000 cells per well) and harvested after 1, 2 and 4 days. At the time points, 0.1 volume of MTT solution was dispensed into each well and incubated for 4 h at 37 1C. Supernatants were collected and mixed with dimethyl sulfoxide (EMD Biosciences, Gibbstown, NJ, USA), and spectrophotometrical absorbances (550 nm) were measured using a Nanodrop 2000 (Thermo Scientific, West Palm Beach, FL, USA). Finally, absorbance values at each time point were normalized to the absorbance value of a negative control, which was a condition in which cells were cultured on TCPS for the same durations without AAV/ELPs.
